at-home testing

The company is initially targeting the large employer market with its app-connected biometric monitoring tools.

The company projects that sales of its testing kits will triple by the end of 2020.

Lucira's molecular testing kit allows individuals to collect their own nasal sample and insert it into a device that provides results in under 30 minutes. The company is aiming to sell the single-use tests for roughly $50.

This news comes just months after it closed its $25 million Series B round. 

The companies are reported to have agreed on a $9 million deal with milestones for Inui Health (formerly known as Scanadu).

The Cue Health Monitoring System can deliver its results through a smartphone dashboard, and is intended for use by health professionals and consumers alike.

The startup, which specializes in a range of at-home testing kits, so far only offers a COVID-19 testing product for point-of-care providers.

Using a designated kit ordered by a doctor, patients will be able to self-swab and mail their samples to LabCorp testing facilities. The self-collection kits will be available in "most states" in the coming weeks.

Also Cue Health scores $13 million from the department of Health and Human Services Biomedical Advanced Research and Development authority in order to fund its portable COVID-19 diagnostic test.

Nurx, Carbon Health and Everlywell have officially halted their mail-order testing-kit services. But at least one startup is still moving to secure an Emergency Use Authorization for its at-home rapid serology diagnostic.